Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLOT Regimen Conversion Therapy for Gastric/GEJ Adenocarcinoma
NCT03451942Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Feb 2018
- Primary completion
- Sep 2019
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel, oxaliplatin, folinic acid and fluorouracil in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Progression-free Survival at 2 years. Status: unknown.
02
Drugs
docetaxeloxaliplatinfolinic acidfluorouracil
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03451942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03451942.